(MedPage Today) — A potentially blinding condition is a very rare side effect of the GLP-1 receptor agonist semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded.
Following a review of all available data, the…
Source link : https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938
Author :
Publish date : 2025-06-06 15:06:00
Copyright for syndicated content belongs to the linked Source.
